Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 3 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 7INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Giant Cell Tumor of Bone 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Vitamin D × Clear all
NCT04255576 2022-10-14

Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone

Shanghai JMT-Bio Inc.

Phase 1/2 Unknown
139 enrolled

Giant Cell Tumor of Bone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡